Clinical trial
An Interventional, Open-label, Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
NCT07281833 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Interventional, Open-label, Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
- Lead sponsor
- Women's Cancer Study Group GmbH
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- November 27, 2025
- Completion date
- March 31, 2030
- Enrollment
- 250 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
advanced breast cancer, breast cancer, her2-negative breast cancer, hr-positive breast cancer, metastatic breast cancer